Multicentre gene therapy for OTOF -related deafness followed up to 2.5 years - Nature

In a multicentre trial of AAV1-hOTOF gene therapy involving 42 participants aged 0.8–32.3 years with autosomal recessive deafness 9, treatment demonstrated safety, tolerability, and improved hearing a...